Sobi gets US FDA Fast Track for pacritinib in VEXAS
Sobi North America said the US FDA granted Fast Track designation to pacritinib for treatment of VEXAS syndrome.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.